Dipal Doshi - Jan 9, 2023 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role: President and CEO, Director
Signature: /s/ Jared Cohen, as Attorney-in-Fact
Stock symbol: TRDA
Transactions as of: Jan 9, 2023
Transactions value $: -$36,196
Form type: 4
Date filed: 1/10/2023, 03:40 PM
Previous filing: Dec 29, 2022
Next filing: Jan 30, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRDA	Common Stock	Sale	-$36.2K	-2.41K	-1.43%	$15.02	166K	Jan 9, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.